Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Accumulated Expenses: 2023-2024

Historic Accumulated Expenses for Compass Therapeutics (CMPX) over the last 2 years, with Dec 2024 value amounting to $6.3 million.

  • Compass Therapeutics' Accumulated Expenses rose 197.81% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 197.81%. This contributed to the annual value of $6.3 million for FY2024, which is 150.08% up from last year.
  • According to the latest figures from FY2024, Compass Therapeutics' Accumulated Expenses is $6.3 million, which was up 150.08% from $2.5 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Accumulated Expenses registered a high of $6.3 million during FY2024, and its lowest value of $2.5 million during FY2023.
  • Moreover, its 2-year median value for Accumulated Expenses was $4.4 million (2023), whereas its average is $4.4 million.
  • Data for Compass Therapeutics' Accumulated Expenses shows a peak YoY surged of 150.08% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Compass Therapeutics' Accumulated Expenses stood at $2.5 million in 2023, then spiked by 150.08% to $6.3 million in 2024.